Noile-Immune Biotech Inc.
ノイルイミューン・バイオテック(株)
2026/09/18 Updated
Market Cap:
$37.9M (¥5.9B)
Stock Price:
$0.87 (¥137)
Exchange Rate: 1 USD = ¥156.99
Stock Price Chart
2026/09/18 Updated0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
1.66
PBR (Price to Book Ratio)
vs Industry Avg: +0.4
0.00%
Dividend Yield
vs Industry Avg: -2.95%
Price Trend
2026/09/18 UpdatedShort-term
5-Day MA
-0.72%
Near-term
25-Day MA
-4.73%
Mid-term
75-Day MA
+1.68%
Long-term
200-Day MA
-4.83%
Price & Trading Details
2026/09/18 UpdatedPRICE
Previous Close
¥136
Open
¥133
High
¥137
Low
¥133
Close
¥137
TRADING
Volume
161,200
Average Volume
104,346
Turnover
¥22,084,400
Min. Purchase
¥13,700
Analyst Recommendations 1 analysts
Updated 2026/09/01Target Price (Mean)
¥440
None
¥440
High
¥440
Median
¥440
Low
+201% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.
Earnings Calendar
Updated 2026/09/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/12 | ¥-5.51 | ¥-5.05 | +8.4% |
| 2026/05/13 | ¥-5.05 | ¥-3.54 | +29.9% |
| 2026/02/12 | ¥-5.42 | ¥-4.36 | +19.6% |
| 2025/11/12 | ¥-11.04 | ¥-4.46 | +59.6% |
Shareholder Composition
Updated 2026/09/0156.9%
Insider Holdings
3.1%
Institutional
40.0%
Public Float
1
Institutional Holders
Insider Holdings
56.9%
Institutional
3.1%
Public Float
40.0%
Financial Performance
2026/09/13 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥626M | ¥317M | ¥8M | ¥5M |
| Gross Profit | ¥619M | ¥315M | ¥7M | ¥5M |
| Operating Income | -¥106M | -¥775M | -¥1,069M | -¥797M |
| Pretax Income | -¥106M | -¥775M | -¥1,069M | -¥797M |
| Net Income | -¥387M | -¥1,130M | -¥964M | -¥794M |
| EPS | -¥9.87 | -¥27.25 | -¥22.28 | -¥18.33 |
| Operating Margin | -16.99% | -244.74% | -14,092.29% | -15,945.08% |
| Balance Sheet | ||||
| Total Assets | ¥4,641M | ¥5,779M | ¥4,800M | ¥4,012M |
| Total Equity | ¥4,301M | ¥5,687M | ¥4,725M | ¥3,932M |
| Total Liabilities | ¥340M | ¥91M | ¥75M | ¥80M |
| Cash | ¥4,521M | ¥5,556M | ¥4,671M | ¥3,918M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 92.67% | 98.42% | 98.44% | 98.01% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥107M | -¥873M | -¥888M | -¥752M |
| Investing CF | - | -¥5M | ¥1M | -¥0M |
| Financing CF | ¥488M | ¥1,913M | ¥3M | -¥0M |
| Free CF | -¥107M | -¥873M | -¥888M | -¥752M |
| Efficiency | ||||
| ROE | -8.99% | -19.87% | -20.41% | -20.18% |
| ROA | -8.33% | -19.55% | -20.09% | -19.78% |
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥440
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
English Name
Noile-Immune Biotech Inc.
Japanese Name
ノイルイミューン・バイオテック(株)
Stock Code
4893.T (JPX)
Sector / Industry
Healthcare / Biotechnology
Website
https://www.noile-immune.com
Employees
23
About
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
Data provided by Yahoo Finance
